Xiao X, Gan P, Yu M, Li J, Han Q
Department of Endocrinology, First Affiliated Hospital of Hubei Medical University, Wuhan.
Chin Med Sci J. 1996 Sep;11(3):170-3.
In this study, we investigated the effect of captopril (CPT) on glomerular filtration rate (GFR), effective renal plasma flow (ERPF), filtration fraction (FF), urinary albumin excretion (UAE) and daily urinary excretion of thromboxane B2 (TXB2) and 6-keto- prostaglandin F1a (6-keto-PGF1a) in 29 normotensive non-insulin-dependent diabetes (NIDDM) patients without clinically discernible nephropathy. Before treatment, urinary excretion 6-keto-PGF1a was significantly increased (P < 0.05) in 29 NIDDM patients compared with 25 health subjects matched for age and sex. The values of GFR and FF were significantly higher (P < 0.01 and P < 0.005, respectively) in NIDDM than in normal volunters, whereas ERPF was comparable in both groups. Meanwhile we observed that UAE of early NIDDM was increased before treatment. After CPT treatment, GFR, FF, UAE and urinary excretion of 6-keto-PGF1a were significantly reduce (all P < 0.005) compared with those of NIDDM before treatment. These data indicated that CPT is effective in lowering glomerular filtration pressure and ameliorating microalbuminuria in the normotensive early NIDDM.
在本研究中，我们调查了卡托普利（CPT）对29例无临床可辨肾病的血压正常的非胰岛素依赖型糖尿病（NIDDM）患者的肾小球滤过率（GFR）、有效肾血浆流量（ERPF）、滤过分数（FF）、尿白蛋白排泄量（UAE）以及血栓素B2（TXB2）和6-酮-前列腺素F1α（6-酮-PGF1α）每日尿排泄量的影响。治疗前，与25例年龄和性别匹配的健康受试者相比，29例NIDDM患者的尿6-酮-PGF1α排泄量显著增加（P<0.05）。NIDDM患者的GFR和FF值显著高于正常志愿者（分别为P<0.01和P<0.005），而两组的ERPF相当。同时，我们观察到早期NIDDM患者治疗前UAE增加。CPT治疗后，与治疗前的NIDDM患者相比，GFR、FF、UAE和6-酮-PGF1α的尿排泄量显著降低（均P<0.005）。这些数据表明，CPT对降低血压正常的早期NIDDM患者的肾小球滤过压和改善微量白蛋白尿有效。
